Doctor On Demand passes 1M virtual visits

Doctor On Demand, a national healthcare service delivered through telehealth technology, has passed one million video visits.

Doctor On Demand provides access to board-certified physicians, psychiatrists and licensed psychologists through video visits, as well as integrated lab services for an advanced range of telehealth services. Completed in just over four years, the accomplishment comes after Doctor On Demand’s $74 million Series C financing round. As the company continues to grow, it projects to reach two million visits by summer 2019.

Launched in December 2013, Doctor On Demand has seen triple-digit growth year-over-year and is known for its high-quality and cost-effective care. The service is accredited by the American Telemedicine Association (ATA), National Committee for Quality Assurance (NCQA) and HITRUST. It is also the virtual care provider of four Fortune 10 companies and partners with more than two dozen health plans.

“Our mission is to improve the world’s health through compassionate care and innovation. We built Doctor On Demand four years ago to provide the easiest, most convenient access to some of the best care in the country,” Hill Ferguson, CEO of Doctor On Demand, said in a press release. “We look forward to continuing to expand our platform capabilities and shape the future of healthcare.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.